Barclays downgrades Arkema (0IB0) to a Hold
Don't Miss TipRanks' Half-Year Sale
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
According to TipRanks, Stewart is ranked #5876 out of 9670 analysts.
Currently, the analyst consensus on Arkema is a Moderate Buy with an average price target of €79.09, implying a 28.81% upside from current levels. In a report released on June 30, Goldman Sachs also maintained a Hold rating on the stock with a €69.00 price target.
The company has a one-year high of €88.35 and a one-year low of €57.75. Currently, Arkema has an average volume of 67.05K.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Inspire Medical Systems Stock (INSP) Dives After Reporting a Q2 Beat & Guidance Cut
Inspire Medical Systems (INSP) stock plummeted on Tuesday following the release of the medical technology company's Q2 2025 earnings report. This started with adjusted earnings per share of 45 cents, compared to Wall Street's estimate of 20 cents. The company's adjusted EPS also increased 40.63% year-over-year from 32 cents. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Inspire Medical Systems reported revenue of $217.1 million in Q2, which surpassed analysts' estimate of $214.49 million. It was also up 11% from the $195.88 million reported in the second quarter of 2024. This was fueled by the launch of its Inspire V system in the U.S. However, investors' hopes were hurt when Inspire Medical Systems Chairman and CEO Tim Herbert noted that 'the U.S. commercial launch is progressing slower than expected, and the timeline to complete the full transition to Inspire V has been pushed forward, which will impact financial results for the year.' Inspire Medical Systems Guidance Inspire Medical Systems lowered its 2025 guidance in its latest earnings report. It now expects revenue for the year to range from $900 million to $910 million, compared to its previous estimate of $940 to $955 million. This would also see it miss Wall Street's 2025 revenue estimate of $914.74 million. Inspire Medical Systems stock was down 30.48% in pre-market trading on Tuesday, following a 3.05% rally yesterday. The shares have also decreased 29.9% year-to-date and 11.6% over the past 12 months. The guidance cut announced by Inspire Medical Systems has already resulted in several lowered price targets, including UBS analyst Danielle Antalffy cutting her price target for INSP shares to $230 from $270. Is Inspire Medical Systems Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Inspire Medical Systems is Strong Buy, based on 10 Buy and three Hold ratings over the past 12 months. With that comes an average INSP stock price target of $210.09, representing a potential 61.67% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today's earnings report.
Business Insider
an hour ago
- Business Insider
RBC Capital Remains a Buy on Definity Financial Corp. (DFY)
RBC Capital analyst Bart Dziarski maintained a Buy rating on Definity Financial Corp. yesterday and set a price target of C$87.00. The company's shares closed yesterday at C$73.95. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Dziarski is a 2-star analyst with an average return of 1.7% and a 43.75% success rate. Dziarski covers the Financial sector, focusing on stocks such as Fairfax Financial Holdings, Intact Financial Corporation, and Definity Financial Corp.. In addition to RBC Capital, Definity Financial Corp. also received a Buy from TR | OpenAI – 4o's Wesley Roofguard in a report issued on August 1. However, yesterday, Raymond James maintained a Hold rating on Definity Financial Corp. (TSX: DFY). Based on Definity Financial Corp.'s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of C$51.4 million and a net profit of C$92 million. In comparison, last year the company earned a revenue of C$1 billion and had a net profit of C$105.2 million Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DFY in relation to earlier this year.
Business Insider
an hour ago
- Business Insider
GAP Airports reports July traffic up 1.8%
Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for July 2025, compared with July 2024. During this period, the total number of terminal passengers at GAP's 12 Mexican airports increased by 1.8%, compared to July 2024. Guadalajara and Puerto Vallarta airports presented an increase in passenger traffic of 0.7% and 0.4%, respectively, while Los Cabos remained flat and Tijuana airport decreased 3.1%, compared to July 2024. On the other hand, Montego Bay presented an increase in passenger traffic of 15.2%, compared to July 2024. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
